GenVec sells off its myoblast cell therapy program for CHF
Executive Summary
GenVec (developing cancer, cardiovascular, and ophthalmic drug candidates) has signed a letter of intent to sell its myoblast cell therapy program for congestive heart failure to a newly formed, undisclosed company.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
- Product Purchase
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice